Document is current
Any future updates will be listed below
-
Authors
Mavarani, Laven https://orcid.org/0000-0001-7414-0899
Albayrak-Rena, Sarah
Potthoff, Anja https://orcid.org/0000-0001-5323-1281
Hower, Martin https://orcid.org/0000-0001-5967-5238
Dolff, Sebastian https://orcid.org/0000-0001-5549-1706
Sammet, Stefanie
Maischack, Felix
Schadendorf, Dirk https://orcid.org/0000-0003-3524-7858
Schmidt, Börge
Esser, Stefan
,
-
Funding
Funding for this research was provided by:
ViiV Healthcare (113189)
Gilead Sciences (CO-DE-985-5951)
Merck Sharp and Dohme (IIS # 60086 Esser)
Janssen-Cilag (PCSIDV004565)
Universitätsklinikum Essen
- License Information
-
More Information
Article History
Received: 20 December 2022
Accepted: 17 February 2023
First Online: 17 March 2023
Declarations
:
: SE has received honoraria for lectures or advisory boards and his institution has received research grants from ViiV Healthcare, Gilead, MSD, GSK and Janssen. AP has received honoraria for lectures or advisory boards and his institution has received research grants from ViiV Healthcare, Gilead, GSK, Abbvie and Abviris.
: The HIVH study has been registered at Clinical Trails (NCT04330287) and has been approved by the local ethics committee of the University Duisburg-Essen (14-5874-BO). All participants gave written informed consent. The HNR study was approved by the ethics committee of the University of Duisburg-Essen and comprises extended quality management procedures including a certification according to DIN ISO 9001:2000. Written informed consent was obtained from all participants. The study was conducted according to the guidelines and recommendations for ensuring Good Epidemiological Practice ().
